Banner - About Welchol
Consider Welchol as add-on therapy for lowering LDL-C and A1C
In the appropriate patient, as an adjunct to diet and exercise, Welchol (colesevelam HCI) is the only bile acid sequestrant FDA approved to provide both LDL-C and A1C reductions in adults with primary hyperlipidemia and type 2 diabetes mellitus (T2DM) when used in combination with a statin and metformin.
The Welchol difference–more reasons to prescribe Welchol:
- Welchol is the only FDA-approved therapy for lowering LDL-C and A1C with one active ingredient in adults with primary hyperlipidemia and T2DM1
- Prescribed by physicians to reduce LDL-C for over 15 years with over 22 million prescriptions written
- In T2DM clinical trials, not associated with weight gain
- Welchol works in combination with the standards of care, statins and metformin, to reduce LDL-C and A1C
- Welchol does not require a dosage adjustment in patients with hepatic impairment or mild or moderate renal impairment (Welchol has not been studied in patients with severe renal impairment)
- In T2DM clinical trials, incidence of hypoglycemia was comparable between Welchol and placebo
- Welchol delivers efficacy without being systemically absorbed and is not metabolized by the liver or kidneys1
Welchol is contraindicated in patients with a history of bowel obstruction, serum triglyceride (TG) concentrations >500 mg/dL, and in patients with a history of hypertriglyceridemia-induced pancreatitis.
Welchol may increase the exposure of co-administered metformin extended release (ER). Patients receiving concomitant metformin ER and colesevelam should be monitored for clinical response as is usual for the use of antidiabetes drugs.
About Story Navigation
Important Safery Information
Welchol is indicated as an adjunct to diet and exercise to:
- reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin)
- reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia, as monotherapy or in combination with a statin after failing an adequate trial of diet therapy
- improve glycemic control in adults with type 2 diabetes mellitus
- Welchol should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis
- Welchol has not been studied in type 2 diabetes in combination with a dipeptidyl peptidase-4 inhibitor
- Welchol has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias
- Welchol has not been studied in children younger than 10 years of age or in premenarchal girls
IMPORTANT SAFETY INFORMATION ABOUT WELCHOL (colesevelam HCI)
Welchol is contraindicated in:
- individuals with a history of bowel obstruction
- those with serum triglyceride (TG) concentrations of >500 mg/dL, or
- those with a history of hypertriglyceridemia-induced pancreatitis.
The effect of Welchol on cardiovascular morbidity and mortality has not been determined.
Welchol can increase serum TG concentrations particularly when used in combination with pioglitazone, sulfonylureas, or insulin. Caution should be exercised when treating patients with TG levels >300 mg/dL.
Welchol may decrease the absorption of fat-soluble vitamins A, D, E, and K. Patients on vitamin supplements should take their vitamins at least 4 hours prior to Welchol. Caution should be exercised when treating patients with a susceptibility to vitamin K or fat-soluble vitamin deficiencies.
Caution should also be exercised when treating patients with gastroparesis, gastrointestinal motility disorders, a history of major gastrointestinal tract surgery, and when treating patients with dysphagia and swallowing disorders.
Welchol interacts with some drugs. Drugs with a known interaction with colesevelam (cyclosporine, glimepiride, glipizide, glyburide, levothyroxine, olmesartan medoxomil, oral contraceptives [ethinyl estradiol, norethindrone], and metformin extended release [ER]) should be administered at least 4 hours prior to Welchol. Drugs that have not been tested for interaction with colesevelam, especially those with a narrow therapeutic index, should also be administered at least 4 hours prior to Welchol. Alternatively, the physician should monitor drug levels of the co-administered drug.
To avoid esophageal distress, Welchol for Oral Suspension should not be taken in its dry form.
Due to tablet size, Welchol for Oral Suspension is recommended for, but not limited to, use in the pediatric population as well as in any patient who has difficulty swallowing tablets.
Phenylketonurics: Welchol for Oral Suspension contains 27 mg phenylalanine per 3.75 gram dose.
In clinical trials, the adverse reactions observed in ≥2% of patients, and more commonly with Welchol than placebo, regardless of investigator assessment of causality seen in:
- Adult patients with Primary Hyperlipidemia were: constipation, dyspepsia, nausea, accidental injury, asthenia, pharyngitis, flu syndrome, rhinitis, and myalgia
- Pediatric patients with heFH primary hyperlipidemia were: nasopharyngitis, headache, fatigue, creatine phosphokinase increase, rhinitis, and vomiting
- Adult patients with Type 2 Diabetes were: constipation, hypoglycemia, dyspepsia, nausea, hypertension, and back pain
Post-marketing experience: Due to the voluntary nature of these reports it is not possible to reliably estimate frequency or establish a causal relationship:
- Increased seizure activity or decreased phenytoin levels have been reported in patients receiving phenytoin concomitantly with Welchol
- Reduced International Normalized Ratio (INR) has been reported in patients receiving warfarin concomitantly with Welchol
- Elevated thyroid-stimulating hormone (TSH) has been reported in patients receiving thyroid hormone replacement therapy
- Dysphagia has been reported with both tablet and oral suspension formulations
Welchol is Pregnancy Category B.
Please click here for Full Prescribing Information about Welchol.
Savings Card Offer
To the Patient: You must present this card to pharmacist along with your WELCHOL® (colesevelam HCl) prescription to participate in the program. For patients with commercial insurance, savings per prescription of WELCHOL will apply after the following out-of-pocket expenses are met: $10 per prescription for a 30-day supply of WELCHOL or $0 per prescription for a 90-day supply of WELCHOL. Offer may not be combined with any other program offer or discount for WELCHOL. Savings for WELCHOL are subject to a maximum benefit of $150 per 30-day prescription or $450 per 90-day prescription. If you have questions regarding your eligibility or benefits, or wish to discontinue participation, call (866) 566-4606 (8 AM – 8 PM ET, M-F). When you use this card, you are certifying that you understand the program rules, regulations, and terms and conditions. You are not eligible if you are enrolled in any state or federal health care program, including, but not limited to, Medicare Part D or Medicaid, VA, DOD, or TRICARE/CHAMPUS; or where taxed, restricted, or prohibited by law; or if you do not otherwise comply with the terms of this card. Further, you agree to discontinue using the card if you enroll in any state or federal health care program during the program period. Offer valid in US and Puerto Rico only.
To the Pharmacist: When you use this card, you are certifying that the patient is not enrolled in any federal, state, or other governmental programs for this prescription.
- Submit transaction to McKesson Corporation, using BIN #610524.
- If primary coverage exists, input card information as secondary coverage and transmit using the COB segment of NCPDP transaction. Applicable discounts will be displayed in the transaction response.
- Acceptance of this card and your submission of claims for the WELCHOL ADDvantage Program™ are subject to LoyaltyScript® program Terms and Conditions posted at www.mckesson.com/mprs.
- Patient not eligible if enrolled in any state or federal health care program, including, but not limited to, Medicare Part D or Medicaid, VA, DOD, or TRICARE/CHAMPUS, or where taxed, restricted or prohibited by law. Offer valid in US and Puerto Rico only.
- LoyaltyScript® is not an insurance card. For questions regarding setup, claim transmissions, patient eligibility, or other issues, call LoyaltyScript® for the WELCHOL Savings Plan at (866) 566-4606 (8 AM – 8 PM ET, M-F).
Daiichi Sankyo, Inc., reserves the right to rescind, revoke, or amend this program, at any time, without notice.
Trademarks not owned by Daiichi Sankyo, Inc., are property of their respective owners.